{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:59:12Z","timestamp":1740149952833,"version":"3.37.3"},"reference-count":54,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100007700","name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy Ministry of Research and Innovation within PNCDIIII","doi-asserted-by":"publisher","award":["23PFE\/17.10.2018"],"award-info":[{"award-number":["23PFE\/17.10.2018"]}],"id":[{"id":"10.13039\/501100007700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006730","name":"Ministry of Education and Research","doi-asserted-by":"publisher","award":["PN1N\/2019_19.29.02.01","7PFE\/16.10.2018"],"award-info":[{"award-number":["PN1N\/2019_19.29.02.01","7PFE\/16.10.2018"]}],"id":[{"id":"10.13039\/501100006730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"\u2018Victor Babe\u0219\u2019 National Institute of Pathology, Ministry of Research and Innovation, Romania","doi-asserted-by":"publisher","award":["29N\/2018 PN18.21.01.01","PN1N\/2019_19.29.01.02","7PFE\/2018"],"award-info":[{"award-number":["29N\/2018 PN18.21.01.01","PN1N\/2019_19.29.01.02","7PFE\/2018"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Natalizumab is a humanized monoclonal antibody with high efficacy and\nan acceptable safety profile used in the treatment of patients with multiple sclerosis (MS).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>Our aim was to report data regarding long-term administration of Natalizumab in patients\nwith Relapsing-Remitting Multiple Sclerosis (RRMS) from our clinic.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A retrospective observational study was performed including RRMS patients who underwent\ntreatment with \u2265 24 Natalizumab infusions. We analyzed EDSS values, the relapse rate and\nthe rate and type of adverse events related to Natalizumab administration.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>51 subjects were included with a predominance of women (62.74%), with an average age\nof 40.43\u00b11.49 years, a mean disease duration of 9.86\u00b10.7 years and mean number of Natalizumab\ninfusions of 45.58\u00b12.74. An increased number of patients (80.39%) were relapse-free and a mild reduction\nof the mean EDSS value following Natalizumab initiation in patients who had not been\ntreated with other disease modifying therapies anteriorly was observed. Among the encountered adverse\nevents such as increased liver transaminases (13.72%), local infections (7.84%) and dysmenorrhea\nin one patient were registered in this study. The rate of severe adverse events was 3.92 and\nno cases of Progressive Multifocal Leukoencephalopathy (PML) were registered.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>Natalizumab proves to be effective, has an adequate safety profile and can be administered\nwith good tolerability for a rather extended period of time, provided that the patients are closely\nmonitored.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527320666210827113733","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T04:29:00Z","timestamp":1630297740000},"page":"326-334","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Data Regarding Long-Term Administration of Natalizumab\nDerived from a Neurology Department along with Literature Review"],"prefix":"10.2174","volume":"21","author":[{"given":"Eugenia Irene","family":"Davidescu","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania | Neurology Department, Colentina Clinical Hospital, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Odajiu","sequence":"additional","affiliation":[{"name":"Neurology Department, Colentina Clinical Hospital, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin-Drago\u0219","family":"Sandu","sequence":"additional","affiliation":[{"name":"Neurology Department, Colentina Clinical Hospital, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Ghergu","sequence":"additional","affiliation":[{"name":"Neurology Department, Colentina Clinical Hospital, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimela","family":"Luca","sequence":"additional","affiliation":[{"name":"Neurology Department, Colentina Clinical Hospital, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafin Fior","family":"Mure\u0219anu","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Iuliu Hatieganu\nUniversity of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4826-2598","authenticated-orcid":true,"given":"Bogdan Ovidiu","family":"Popescu","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania | Neurology Department, Colentina Clinical Hospital, Bucharest, Romania | Laboratory of Cell Biology, Neurosciences\nand Experimental Myology, \u201cVictor Babe\u0219\u201d National Institute of Pathology, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","year":"2019","unstructured":"Global, regional, and national burden of multiple sclerosis 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol GBD 2016 Multiple Sclerosis Collaborators2019,18(3),269-285","journal-title":"Lancet Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/imt-2016-0113","volume":"9","author":"Delbue S.","year":"2017","unstructured":"Delbue S.; Comar M.; Ferrante P.; Natalizumab treatment of multiple sclerosis: New insights. Immunotherapy 2017,9(2),157-171","journal-title":"Immunotherapy"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2013.05.010","volume":"333","author":"Lassmann H.","year":"2013","unstructured":"Lassmann H.; Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013,333(1-2),1-4","journal-title":"J Neurol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0092-8674(90)90661-W","volume":"60","author":"Elices M.J.","year":"1990","unstructured":"Elices M.J.; Osborn L.; Takada Y.; Crouse C.; Luhowskyj S.; Hemler M.E.; Lobb R.R.; VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4\/fibronectin binding site. Cell 1990,60(4),577-584","journal-title":"Cell"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"Yednock T.A.","year":"1992","unstructured":"Yednock T.A.; Cannon C.; Fritz L.C.; Sanchez-Madrid F.; Steinman L.; Karin N.; Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992,356(6364),63-66","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"7196","DOI":"10.4049\/jimmunol.0901404","volume":"184","author":"Jain P.","year":"2010","unstructured":"Jain P.; Coisne C.; Enzmann G.; Rottapel R.; Engelhardt B.; Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis. J Immunol 2010,184(12),7196-7206","journal-title":"J Immunol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/ijms18050940","volume":"18","author":"Clerico M.","year":"2017","unstructured":"Clerico M.; Artusi C.A.; Liberto A.D.; Rolla S.; Bardina V.; Barbero P.; Mercanti S.F.; Durelli L.; Natalizumab in multiple sclerosis: long-term management. Int J Mol Sci 2017,18(5),940","journal-title":"Int J Mol Sci"},{"year":"2006","key":"ref=8","unstructured":"Human medicines. European Medicines Agency Available from: (Accessed September 15, 2020).2006"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.53.3.466","volume":"53","author":"Tubridy N.","year":"1999","unstructured":"Tubridy N.; Behan P.O.; Capildeo R.; Chaudhuri A.; Forbes R.; Hawkins C.P.; Hughes R.A.; Palace J.; Sharrack B.; Swingler R.; Young C.; Moseley I.F.; MacManus D.G.; Donoghue S.; Miller D.H.; The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999,53(3),466-472","journal-title":"Neurology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"Miller D.H.","year":"2003","unstructured":"Miller D.H.; Khan O.A.; Sheremata W.A.; Blumhardt L.D.; Rice G.P.A.; Libonati M.A.; Willmer-Hulme A.J.; Dalton C.M.; Miszkiel K.A.; O\u2019Connor P.W.; A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003,348(1),15-23","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","volume":"72","author":"Goodman A.D.","year":"2009","unstructured":"Goodman A.D.; Rossman H.; Bar-Or A.; Miller A.; Miller D.H.; Schmierer K.; Lublin F.; Khan O.; Bormann N.M.; Yang M.; Panzara M.A.; Sandrock A.W.; GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009,72(9),806-812","journal-title":"Neurology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","volume":"68","author":"Miller D.H.","year":"2007","unstructured":"Miller D.H.; Soon D.; Fernando K.T.; MacManus D.G.; Barker G.J.; Yousry T.A.; Fisher E.; O\u2019Connor P.W.; Phillips J.T.; Polman C.H.; Kappos L.; Hutchinson M.; Havrdova E.; Lublin F.D.; Giovannoni G.; Wajgt A.; Rudick R.; Lynn F.; Panzara M.A.; Sandrock A.W.; MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007,68(17),1390-1401","journal-title":"Neurology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"Rudick R.A.","year":"2006","unstructured":"Rudick R.A.; Stuart W.H.; Calabresi P.A.; Confavreux C.; Galetta S.L.; Radue E-W.; Lublin F.D.; Weinstock-Guttman B.; Wynn D.R.; Lynn F.; Panzara M.A.; Sandrock A.W.; Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006,354(9),911-923","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","volume":"85","author":"Butzkueven H.","year":"2014","unstructured":"Butzkueven H.; Kappos L.; Pellegrini F.; Trojano M.; Wiendl H.; Patel R.N.; Zhang A.; Hotermans C.; Belachew S.; Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry 2014,85(11),1190-1197","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13760-014-0308-9","volume":"114","author":"van Pesch V.","year":"2014","unstructured":"van Pesch V.; Bartholom&#xE9; E.; Bissay V.; Bouquiaux O.; Bureau M.; Caekebeke J.; Debruyne J.; Declercq I.; Decoo D.; Denayer P.; De Smet E.; D\u2019hooghe M.; Dubois B.; Dupuis M.; Sankari S.E.; Geens K.; Guillaume D.; van Landegem W.; Lysandropoulos A.; de Noordhout A.M.; Medaer R.; Melin A.; Peeters K.; Ba R.P.; Retif C.; Seeldrayers P.; Symons A.; Urbain E.; Vanderdonckt P.; Van Ingelghem E.; Vanopdenbosch L.; Vanroose E.; Van Wijmeersch B.; Willekens B.; Willems C.; Sindic C.; Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: Subgroup analysis of the natalizumab observational program. Acta Neurol Belg 2014,114(3),167-178","journal-title":"Acta Neurol Belg"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","volume":"83","author":"O\u2019Connor P.","year":"2014","unstructured":"O\u2019Connor P.; Goodman A.; Kappos L.; Lublin F.; Polman C.; Rudick R.A.; Hauswirth K.; Cristiano L.M.; Forrestal F.; Duda P.; Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 2014,83(1),78-86","journal-title":"Neurology"},{"key":"ref=17","first-page":"399","volume":"59","author":"Sousa L.","year":"2014","unstructured":"Sousa L.; de Sa J.; Sa M.J.; Cerqueira J.J.; Martins-Silva A.; The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: A retrospective study. Rev Neurol 2014,59(9),399-406","journal-title":"Rev Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","volume":"16","author":"Oturai A.B.","year":"2009","unstructured":"Oturai A.B.; Koch-Henriksen N.; Petersen T.; Jensen P.E.; Sellebjerg F.; Sorensen P.S.; Efficacy of natalizumab in multiple sclerosis patients with high disease activity: A Danish nationwide study. Eur J Neurol 2009,16(3),420-423","journal-title":"Eur J Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1468-1331.2009.02728.x","volume":"17","author":"Putzki N.","year":"2010","unstructured":"Putzki N.; Yaldizli O.; M&#xE4;urer M.; Cursiefen S.; Kuckert S.; Klawe C.; Maschke M.; Tettenborn B.; Limmroth V.; Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: Results from a multi-center study in German speaking countries. Eur J Neurol 2010,17(1),31-37","journal-title":"Eur J Neurol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10072-010-0344-z","volume":"31","author":"Sangalli F.","year":"2011","unstructured":"Sangalli F.; Moiola L.; Bucello S.; Annovazzi P.; Rizzo A.; Radaelli M.; Vitello G.; Grimaldi L.M.E.; Ghezzi A.; Martinelli V.; Comi G.; Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study. Neurol Sci 2011,31(Suppl. 3),299-302","journal-title":"Neurol Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1017\/S0317167100011811","volume":"38","author":"Krysko K.M.","year":"2011","unstructured":"Krysko K.M.; O\u2019Connor P.W.; The toronto observational study of natalizumab in multiple sclerosis. Can J Neurol Sci 2011,38(3),422-428","journal-title":"Can J Neurol Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1007\/s00415-012-6414-9","volume":"259","author":"Fern&#xE1;ndez O.","year":"2012","unstructured":"Fern&#xE1;ndez O.; Oreja-Guevara C.; Arroyo R.; Izquierdo G.; P&#xE9;rez J.L.; Montalban X.; Natalizumab treatment of multiple sclerosis in Spain: Results of an extensive observational study. J Neurol 2012,259(9),1814-1823","journal-title":"J Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/WNF.0b013e31824644e6","volume":"35","author":"Kallweit U.","year":"2012","unstructured":"Kallweit U.; Jelcic I.; Braun N.; Fischer H.; Z&#xF6;rner B.; Schreiner B.; Sokolov A.A.; Martin R.; Weller M.; Linnebank M.; Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: Real-life data from a Swiss cohort. Clin Neuropharmacol 2012,35(2),77-80","journal-title":"Clin Neuropharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/039463201402700201","volume":"27","author":"Totaro R.","year":"2014","unstructured":"Totaro R.; Lugaresi A.; Bellantonio P.; Danni M.; Costantino G.; Gasperini C.; Florio C.; Pucci E.; Maddestra M.; Spitaleri D.; Lus G.; Ardito B.; Farina D.; Rossi M.; Di Carmine C.; Altobelli E.; Maccarone B.; Casalena A.; De Luca G.; Travaglini D.; Di Ioia M.; Di Tommaso V.; Fantozzi R.; Ruggieri S.; Provinciali L.; De Riso S.; Mundi C.; Fuiani A.; Galgani S.; Ruggieri S.; Maniscalco G.T.; Giuliani G.; Cartechini E.; Petretta V.; Fratta M.; Alfieri G.; Gatto M.; Carolei A.; Natalizumab treatment in multiple sclerosis patients: A multicenter experience in clinical practice in Italy. Int J Immunopathol Pharmacol 2014,27(2),147-154","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000351568","volume":"22","author":"Alroughani R.","year":"2013","unstructured":"Alroughani R.; Al Hashel J.; Thussu A.; Ahmed S.F.; Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait. Med Princ Pract 2013,22(5),495-499","journal-title":"Med Princ Pract"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1212\/WNL.0000000000002105","volume":"85","author":"De Stefano N.","year":"2015","unstructured":"De Stefano N.; Stromillo M.L.; Giorgio A.; Battaglini M.; Bartolozzi M.L.; Amato M.P.; Sormani M.P.; Long-term assessment of no evidence of disease activity in relapsing-remitting MS. Neurology 2015,85(19),1722-1723","journal-title":"Neurology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"Rotstein D.L.","year":"2015","unstructured":"Rotstein D.L.; Healy B.C.; Malik M.T.; Chitnis T.; Weiner H.L.; Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015,72(2),152-158","journal-title":"JAMA Neurol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jns.2016.03.025","volume":"364","author":"Prosperini L.","year":"2016","unstructured":"Prosperini L.; Fanelli F.; Pozzilli C.; Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis. J Neurol Sci 2016,364,145-147","journal-title":"J Neurol Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.intimp.2017.03.006","volume":"46","author":"Correia I.","year":"2017","unstructured":"Correia I.; Batista S.; Galego O.; Marques I.B.; Jesus-Ribeiro J.; Martins A.I.; Nunes C.; Mac&#xE1;rio M.C.; Cunha L.; Sousa L.; Long-term effectiveness and safety of natalizumab in a Portuguese population. Int Immunopharmacol 2017,46,105-111","journal-title":"Int Immunopharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.msard.2019.05.017","volume":"33","author":"Dekker I.","year":"2019","unstructured":"Dekker I.; Leurs C.E.; Hagens M.H.J.; van Kempen Z.L.E.; Kleerekooper I.; Lissenberg-Witte B.I.; Barkhof F.; Uitdehaag B.M.J.; Balk L.J.; Wattjes M.P.; Killestein J.; Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab. Mult Scler Relat Disord 2019,33,82-87","journal-title":"Mult Scler Relat Disord"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"30S","DOI":"10.1177\/1051228405283901","volume":"15","author":"Bakshi R.","year":"2005","unstructured":"Bakshi R.; Dandamudi V.S.R.; Neema M.; De C.; Bermel R.A.; Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. J Neuroimaging 2005,15(4)(Suppl.),30S-45S","journal-title":"J Neuroimaging"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1136\/jnnp-2012-304094","volume":"84","author":"Popescu V.","year":"2013","unstructured":"Popescu V.; Agosta F.; Hulst H.E.; Sluimer I.C.; Knol D.L.; Sormani M.P.; Enzinger C.; Ropele S.; Alonso J.; Sastre-Garriga J.; Rovira A.; Montalban X.; Bodini B.; Ciccarelli O.; Khaleeli Z.; Chard D.T.; Matthews L.; Palace J.; Giorgio A.; De Stefano N.; Eisele P.; Gass A.; Polman C.H.; Uitdehaag B.M.; Messina M.J.; Comi G.; Filippi M.; Barkhof F.; Vrenken H.; Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013,84(10),1082-1091","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/jon.12586","volume":"29","author":"Eisele P.","year":"2019","unstructured":"Eisele P.; Szabo K.; Ebert A.; Platten M.; Gass A.; Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study. J Neuroimaging 2019,29(2),190-192","journal-title":"J Neuroimaging"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/1352458512473190","volume":"19","author":"Vidal-Jordana A.","year":"2013","unstructured":"Vidal-Jordana A.; Sastre-Garriga J.; P&#xE9;rez-Miralles F.; Tur C.; Tintor&#xE9; M.; Horga A.; Auger C.; R&#xED;o J.; Nos C.; Edo M.C.; Ar&#xE9;valo M.J.; Castill&#xF3; J.; Rovira A.; Montalban X.; Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013,19(9),1175-1181","journal-title":"Mult Scler"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1477-7525-10-155","volume":"10","author":"Stephenson J.J.","year":"2012","unstructured":"Stephenson J.J.; Kern D.M.; Agarwal S.S.; Zeidman R.; Rajagopalan K.; Kamat S.A.; Foley J.; Impact of natalizumab on patient-reported outcomes in multiple sclerosis: A longitudinal study. Health Qual Life Outcomes 2012,10,155","journal-title":"Health Qual Life Outcomes"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2147\/PPA.S134865","volume":"11","author":"Foley J.F.","year":"2017","unstructured":"Foley J.F.; Nair K.V.; Vollmer T.; Stephenson J.J.; Niecko T.; Agarwal S.S.; Watson C.; Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. Patient Prefer Adherence 2017,11,1035-1048","journal-title":"Patient Prefer Adherence"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e58643","DOI":"10.1371\/journal.pone.0058643","volume":"8","author":"Svenningsson A.","year":"2013","unstructured":"Svenningsson A.; Falk E.; Celius E.G.; Fuchs S.; Schreiber K.; Berk&#xF6; S.; Sun J.; Penner I.K.; Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One 2013,8(3),e58643-e58643","journal-title":"PLoS One"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1177\/1352458513517590","volume":"20","author":"Wickstr&#xF6;m A.","year":"2014","unstructured":"Wickstr&#xF6;m A.; Dahle C.; Vrethem M.; Svenningsson A.; Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial. Mult Scler 2014,20(8),1095-1101","journal-title":"Mult Scler"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"Polman C.H.","year":"2006","unstructured":"Polman C.H.; O\u2019Connor P.W.; Havrdova E.; Hutchinson M.; Kappos L.; Miller D.H.; Phillips J.T.; Lublin F.D.; Giovannoni G.; Wajgt A.; Toal M.; Lynn F.; Panzara M.A.; Sandrock A.W.; A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006,354(9),899-910","journal-title":"N Engl J Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/1352458511404271","volume":"17","author":"S&#xF8;rensen P.S.","year":"2011","unstructured":"S&#xF8;rensen P.S.; Jensen P.E.H.; Haghikia A.; Lundkvist M.; Vedeler C.; Sellebjerg F.; Koch-Henriksen N.; Fogdell-Hahn A.; Myhr K-M.; Hillert J.; Gold R.; Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 2011,17(9),1074-1078","journal-title":"Mult Scler"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"69","author":"Calabresi P.A.","year":"2007","unstructured":"Calabresi P.A.; Giovannoni G.; Confavreux C.; Galetta S.L.; Havrdova E.; Hutchinson M.; Kappos L.; Miller D.H.; O\u2019Connor P.W.; Phillips J.T.; Polman C.H.; Radue E-W.; Rudick R.A.; Stuart W.H.; Lublin F.D.; Wajgt A.; Weinstock-Guttman B.; Wynn D.R.; Lynn F.; Panzara M.A.; The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 2007,69(14),1391-1403","journal-title":"Neurology"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/1352458512460604","volume":"19","author":"Vennegoor A.","year":"2013","unstructured":"Vennegoor A.; Rispens T.; Strijbis E.M.; Seewann A.; Uitdehaag B.M.; Balk L.J.; Barkhof F.; Polman C.H.; Wolbink G.; Killestein J.; Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013,19(5),593-600","journal-title":"Mult Scler"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s13365-011-0027-4","volume":"17","author":"Shenoy E.S.","year":"2011","unstructured":"Shenoy E.S.; Mylonakis E.; Hurtado R.M.; Venna N.; Natalizumab and HSV meningitis. J Neurovirol 2011,17(3),288-290","journal-title":"J Neurovirol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1177\/1352458511428082","volume":"18","author":"Kwiatkowski A.","year":"2012","unstructured":"Kwiatkowski A.; Gallois J.; Bilbault N.; Calais G.; Mackowiak A.; Hautecoeur P.; Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2012,18(6),909-911","journal-title":"Mult Scler"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/cns.12067","volume":"19","author":"Fragoso Y.D.","year":"2013","unstructured":"Fragoso Y.D.; Brooks J.B.B.; Gomes S.; de Oliveira F.T.M.; da Gama P.D.; Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci Ther 2013,19(4),280-281","journal-title":"CNS Neurosci Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.msard.2015.08.008","volume":"4","author":"Antezana A.","year":"2015","unstructured":"Antezana A.; Sigal S.; Herbert J.; Kister I.; Natalizumab-induced hepatic injury: A case report and review of literature. Mult Scler Relat Disord 2015,4(6),495-498","journal-title":"Mult Scler Relat Disord"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"Kleinschmidt-DeMasters B.K.","year":"2005","unstructured":"Kleinschmidt-DeMasters B.K.; Tyler K.L.; Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005,353(4),369-374","journal-title":"N Engl J Med"},{"year":"2016","author":"Biogen I.T.","key":"ref=48","unstructured":"Biogen I.T.; PML incidence in patients receiving Tysabri.  Available from: Accessed September 15, 2020.2016"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"Bloomgren G.","year":"2012","unstructured":"Bloomgren G.; Richman S.; Hotermans C.; Subramanyam M.; Goelz S.; Natarajan A.; Lee S.; Plavina T.; Scanlon J.V.; Sandrock A.; Bozic C.; Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012,366(20),1870-1880","journal-title":"N Engl J Med"},{"year":"2016","key":"ref=50","unstructured":"Progressive Multifocal Leukoencephalopathy - updated advice to support early detection. MHRA. Natalizumab (Tysabri) Available from: Accessed September 16, 2020.2016"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"Giovannoni G.","year":"2016","unstructured":"Giovannoni G.; Butzkueven H.; Dhib-Jalbut S.; Hobart J.; Kobelt G.; Pepper G.; Sormani M.P.; Thalheim C.; Traboulsee A.; Vollmer T.; Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord 2016,9(9)(Suppl. 1),S5-S48","journal-title":"Mult Scler Relat Disord"},{"year":"2008","author":"Tysabri F.D.A.","key":"ref=52","unstructured":"Tysabri F.D.A.; Full prescribing information.  Available from: Accessed September 16, 2020.2008"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3389\/fneur.2018.01071","volume":"9","author":"Kaufmann M.","year":"2018","unstructured":"Kaufmann M.; Haase R.; Proschmann U.; Ziemssen T.; Akg&#xFC;n K.; Real-World lab data in natalizumab treated multiple sclerosis patients up to 6 years long-term follow up. Front Neurol 2018,9,1071","journal-title":"Front Neurol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"baz085","DOI":"10.1093\/database\/baz085","volume":"2019","author":"Brown P.","year":"2019","unstructured":"Brown P.; Zhou Y.; Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database (Oxford) RELISH Consortium2019,2019,baz085","journal-title":"Database (Oxford)"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527320666210827113733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/195898\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527320666210827113733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T10:46:54Z","timestamp":1655376414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/195898\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527320666210827113733","relation":{},"ISSN":["1871-5273"],"issn-type":[{"type":"print","value":"1871-5273"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}